Podcasts
Blog
Podcasts
Blog
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
02.16.2024 -
By
Download our free app to listen on your phone
More episodes from Oncology Times - OncTimes Talk